Posted: 06/13/2025 03:09 am
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company focused on developing potentially curative therapies for heart disease, is making important strides in its research agenda. However, its financial performance and executive compensation have recently come under scrutiny.
In 2024, Leone D. Patterson, M.B.A., recorded a total compensation of $1,364,989 as the key executive at Tenaya Therapeutics, a decrease from 2023 when the total compensation was $1,273,581. This fluctuation is predominantly due to variations in option awards, which were valued significantly higher at $831,337 in 2024 compared to $455,297 in 2023. The core salary also declined from $455,000 in 2023 to $349,528 in 2024, reflecting strategic compensation adjustments amid evolving company needs and financial constraints[1][2]. Previously, Whittemore "Whit" Tingley, M.D., Ph.D., received $2,290,907 in 2022, with no stock awards but substantial option awards of $1,668,932, demonstrating the historical reliance on stock-based compensation to align executive incentives with shareholder interests[3].
Despite these internal changes, Tenaya remains focused on its ambitious clinical objectives. Notably, they recently announced an $8 million grant from the California Institute for Regenerative Medicine to support their ongoing RIDGE™-1 clinical trial of TN-401 gene therapy. This development signifies their unwavering commitment to advancing therapies for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, reinforcing their strategic development focus[5]. Moreover, strategic priorities have been set for 2025, including the advancement of TN-201 and TN-401 gene therapies for cardiomyopathies. The introduction of these therapies through clinical trials highlights Tenaya's goal of addressing underlying genetic causes of heart diseases[6].
Recent press releases reveal that Tenaya has not only attracted external funding but also drawn industry interest through the presentation of promising data at high-profile scientific sessions. These presentations at the American College of Cardiology’s annual meeting and positive preclinical findings published in Nature Communications reinforce the potential of Tenaya’s investigational therapies to significantly impact treatment paradigms for hypertrophic cardiomyopathy[10][11].
Financially, the company's stock has faced challenges, with current prices at $0.6008 representing a notable decrease from its year-high of $4.06. Market capitalization stands at approximately $97.73 million, reflecting the company's current valuation in tumultuous market conditions[12]. This underscores the necessity for continued strategic focus and adaptation in a competitive biotech landscape.
:
1. [SEC Filing 2024](https://www.sec.gov/Archives/edgar/data/1858848/000119312525084313/0001193125-25-084313-index.htm)
2. [SEC Filing 2023](https://www.sec.gov/Archives/edgar/data/1858848/000119312524099107/0001193125-24-099107-index.htm)
3. [SEC Filing 2022](https://www.sec.gov/Archives/edgar/data/1858848/000119312523122205/0001193125-23-122205-index.htm)
4. [Company News 2025](https://www.globenewswire.com/news-release/2025/05/16/3082791/0/en/Tenaya-Therapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html)
5. [Press Release Feb 2025](https://www.globenewswire.com/news-release/2025/04/24/3067839/0/en/Tenaya-Therapeutics-Presents-Interim-Data-from-RIDGE-Natural-History-and-Seroprevalence-Study-of-Adults-with-PKP2-associated-ARVC-at-Heart-Rhythm-2025.html)
6. [Press Release Jan 2025](https://www.globenewswire.com/news-release/2025/03/31/3052428/0/en/Tenaya-Therapeutics-Announces-Late-Breaker-Presentation-of-New-Data-from-MyPEAK-1-Phase-1b-2-Clinical-Trial-of-TN-201-at-American-College-of-Cardiology-Annual-Meeting.html)
7. [Company Snapshot](https://www.globenewswire.com/news-release/2025/03/24/3047852/0/en/Tenaya-Therapeutics-Publishes-Preclinical-Data-Demonstrating-TN-201-Enhances-Cardiac-Function-and-Survival-in-MYBPC3-Cardiomyopathy-Models.html)